Amy Baxter from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation		GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration? - 9 days ago A drug for fewer than 1,000 patients? Awareness and diagnosis are key. - 11 days ago With Makary set to face FDA commissioner hearings, how deep do his industry ties run? - 16 days ago Milk-based therapies could be coming. This biotech CEO is aiming to lead the way. - 18 days ago Trump nominees want to slash and burn agencies. Will RFK Jr. and Oz do the same in healthcare? - 25 days ago What might a Trump administration mean for the Biosecure Act? - about 1 month ago The first MASH drug could open the door for others — including GLP-1s - about 1 month ago From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - about 1 month ago What RFK Jr.’s influence could mean for pharma - about 1 month ago A diabetes drug, twice rejected, stumbles again — but its developer persists - about 1 month ago Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s - about 2 months ago 2024 PharmaVoice 100s: Clinical Trial Pros - about 2 months ago Backlash builds against Novo’s Catalent takeover - about 2 months ago 2024 PharmaVoice 100s: Tech and AI Wizards - about 2 months ago Where Big Pharma’s campaign cash is flowing in this election - about 2 months ago FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage - 2 months ago 2024 PharmaVoice 100s: Cardiometabolic All-Stars - 2 months ago As election day nears, Trump and Harris veer in different directions on pharma - 2 months ago How Roche plans to fill a projected $8B sales gap - 3 months ago 3 FDA approval dates to watch in the year’s final push - 3 months ago Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies - 3 months ago FDA adcomm reform talks heat up - 4 months ago Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision - 4 months ago BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings - 4 months ago The drugs hit hardest by Medicare price negotiations - 4 months ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 4 months ago A potential MS ‘game changer’ could bring more safety to the table — even against viruses - 4 months ago M&A is ready to explode, and that’s good news for pharma layoffs - 4 months ago Pharma execs react to final drug price negotiations with Medicare - 4 months ago Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 5 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 5 months ago Read to lead: 6 books pharma execs swear by - 5 months ago 3 Big Pharma cancer drugs facing inflation penalties - 5 months ago Sage’s recent trial failure adds pressure to its two-drug Biogen collab - 5 months ago Where Kamala Harris stands on three key pharma issues - 5 months ago To overcome barriers, cell and gene therapies need outside support - 5 months ago Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 5 months ago Is a better CAR-T cell therapy option on the horizon? - 5 months ago BMS’ long-standing leukemia blockbuster stares down its first generic - 5 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 5 months ago The IRA will lower U.S. drug spending, CMS finds — but not for awhile - 6 months ago Will the real Ozempic please stand up? Lilly, Novo face uphill counterfeit battle - 6 months ago Ahead of its upcoming decision date, a competitor takes aim at KarXT - 6 months ago After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners - 6 months ago The hunt for the brain’s biomarkers - 6 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 6 months ago FDA’s platform designation aims to ease R&D pain points - 6 months ago Behind Big Pharma’s layoffs — is there an end in sight? - 6 months ago Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 7 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 7 months ago